

Howard H Feldman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6825664/howard-h-feldman-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147 papers	38,002 citations	61 h-index	164 g-index
164 ext. papers	44,488 ext. citations	8 avg, IF	6.43 L-index

#	Paper	IF	Citations
147	The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 270-9	1.2	5630
146	Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <i>Science</i> , 2006 , 314, 130-3	33.3	4289
145	Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. <i>Neuron</i> , 2011 , 72, 245-56	13.9	3267
144	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , <i>The</i> , 2007 , 6, 734-46	24.1	3067
143	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , <i>The</i> , 2014 , 13, 614-29	24.1	1985
142	Mild cognitive impairment. <i>Lancet</i> , <i>The</i> , 2006 , 367, 1262-70	40	1703
141	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2017 , 89, 88-100	6.5	1691
140	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. <i>Nature</i> , 2006 , 442, 916-9	50.4	1549
139	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , <i>The</i> , 2016 , 15, 455-532	24.1	921
138	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016 , 12, 292-323	1.2	832
137	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016 , 87, 539-47	6.5	710
136	Treatment of Alzheimer's disease: current status and new perspectives. <i>Lancet Neurology</i> , <i>The</i> , 2003 , 2, 539-47	24.1	590
135	Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 30, 161-78	2.6	570
134	Dementia with Lewy bodies. <i>Lancet Neurology</i> , <i>The</i> , 2004 , 3, 19-28	24.1	560
133	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. <i>Human Molecular Genetics</i> , 2006 , 15, 2988-3001	5.6	463
132	Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. <i>Neuron</i> , 2010 , 68, 654-67	13.9	368
131	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. <i>Alzheimer's and Dementia</i> , 2011 , 7, 367-85	1.2	364

130	Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. <i>Archives of Neurology</i> , 2008 , 65, 45-53		362
129	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010 , 42, 234-9	36.3	361
128	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012 , 33, 1203-14	5.6	278
127	Safety and tolerability of the β -secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. <i>Archives of Neurology</i> , 2012 , 69, 1430-40		266
126	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. <i>Lancet Neurology</i> , 2007 , 6, 501-12	24.1	260
125	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. <i>Brain</i> , 2006 , 129, 3081-90	11.2	259
124	Cholesterol in Alzheimer's disease. <i>Lancet Neurology</i> , 2005 , 4, 841-52	24.1	251
123	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. <i>Human Molecular Genetics</i> , 2008 , 17, 3631-42	5.6	242
122	Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. <i>Lancet</i> , 2016 , 388, 2873-2884	40	214
121	Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. <i>International Psychogeriatrics</i> , 2002 , 14, 389-404	3.4	177
120	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. <i>Lancet Neurology</i> , 2007 , 6, 857-68	24.1	174
119	Emerging therapies for vascular dementia and vascular cognitive impairment. <i>Stroke</i> , 2004 , 35, 1010-7	6.7	173
118	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. <i>Brain</i> , 2012 , 135, 709-22	11.2	172
117	Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. <i>Journal of the American Geriatrics Society</i> , 2003 , 51, 737-44	5.6	161
116	Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. <i>Nature Medicine</i> , 1996 , 2, 1230-5	50.5	152
115	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 196-203	5.5	146
114	The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. <i>Archives of Neurology</i> , 2010 , 67, 161-70		143
113	Diagnosis and treatment of dementia: 2. Diagnosis. <i>Cmaj</i> , 2008 , 178, 825-36	3.5	142

112	Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2015 , 72, 1324-33	17.2	134
111	Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. <i>Depression and Anxiety</i> , 2010 , 27, 417-25	8.4	126
110	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2006 , 20, 732-55	4.6	124
109	Synaptic dysfunction in progranulin-deficient mice. <i>Neurobiology of Disease</i> , 2012 , 45, 711-22	7.5	119
108	Potential for misclassification of mild cognitive impairment: a study of memory scores on the Wechsler Memory Scale-III in healthy older adults. <i>Journal of the International Neuropsychological Society</i> , 2008 , 14, 463-78	3.1	119
107	Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. <i>Cmaj</i> , 2004 , 171, 863-7	3.5	117
106	Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005 , 64, 730-9	3.1	114
105	World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1078-1094	1.2	109
104	Epidemiology and genetics of frontotemporal dementia/Pick's disease. <i>Annals of Neurology</i> , 2003 , 54 Suppl 5, S29-31	9.4	99
103	A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. <i>Brain</i> , 2006 , 129, 853-67	11.2	96
102	Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2005 , 20, 559-69	3.9	94
101	The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 76	9	93
100	Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. <i>Archives of Neurology</i> , 2011 , 68, 488-97		93
99	Therapeutic potential of statins in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2009 , 283, 230-4	3.2	87
98	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , 2021 , 20, 484-496	24.1	86
97	Neuropsychological testing and assessment for dementia. <i>Alzheimer's and Dementia</i> , 2007 , 3, 299-317	1.2	84
96	Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013 , 9, 123-131.e1	1.2	82
95	Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, S2	9	81

94	Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 645-655	6.5	81
93	Clinical phenotypes of Cerebral Amyloid Angiopathy. <i>Journal of the Neurological Sciences</i> , 2007 , 257, 23-30	3.2	80
92	Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. <i>Alzheimer Disease and Associated Disorders</i> , 2005 , 19, 29-36	2.5	80
91	The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. <i>Canadian Journal of Neurological Sciences</i> , 2003 , 30, 237-43	1	78
90	rs5848 polymorphism and serum progranulin level. <i>Journal of the Neurological Sciences</i> , 2011 , 300, 28-32	3.2	64
89	Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease. <i>Stroke</i> , 2008 , 39, 2894-7	6.7	64
88	Mild cognitive impairment. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 645-55	6.5	62
87	Periventricular hyperintensities are associated with elevated cerebral amyloid. <i>Neurology</i> , 2016 , 86, 535-43	4.3	60
86	Differentiating the frontal variant of Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 732-8	3.9	58
85	Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. <i>Alzheimer Disease and Associated Disorders</i> , 2006 , 20, 263-8	2.5	55
84	Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1056-63	5.5	54
83	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019 , 137, 209-226	14.3	54
82	Pharmacodynamics of selective inhibition of β -secretase by avagacestat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013 , 344, 686-95	4.7	52
81	Prevention trials in Alzheimer's disease: an EU-US task force report. <i>Progress in Neurobiology</i> , 2011 , 95, 594-600	10.9	52
80	Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. <i>International Journal of Geriatric Psychiatry</i> , 2009 , 24, 479-88	3.9	50
79	Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. <i>Alzheimer's and Dementia</i> , 2013 , 9, 176-88	1.2	45
78	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. <i>Neurology</i> , 2013 , 81, 1322-31	6.5	45
77	Minimizing misdiagnosis: psychometric criteria for possible or probable memory impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 27, 439-50	2.6	44

76	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. <i>Alzheimer's and Dementia</i> , 2008 , 4, 145-53	1.2	44
75	Dependence as a unifying construct in defining Alzheimer's disease severity. <i>Alzheimer's and Dementia</i> , 2010 , 6, 482-93	1.2	43
74	Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 289-98	1.9	43
73	The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease. <i>Acta Neuropathologica</i> , 2003 , 105, 98-102	14.3	43
72	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). <i>Alzheimer's and Dementia</i> , 2013 , 9, 189-98	1.2	42
71	Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 22, 413-20	3.6	41
70	A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. <i>Canadian Journal of Neurological Sciences</i> , 1997 , 24, 140-5	1	40
69	Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. <i>Neurobiology of Aging</i> , 2014 , 35, 936.e5-12	5.6	37
68	The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. <i>Focus (American Psychiatric Publishing)</i> , 2013 , 11, 96-106	1.1	36
67	Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 28, 244-51	2.6	36
66	Canadian guidelines for the development of antidementia therapies: a conceptual summary. <i>Canadian Journal of Neurological Sciences</i> , 1995 , 22, 62-71	1	36
65	Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. <i>Acta Neuropathologica</i> , 2003 , 105, 543-8	14.3	33
64	Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study. <i>Journal of the Neurological Sciences</i> , 2006 , 240, 7-14	3.2	30
63	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 499-511	1	28
62	Disease progression in vascular cognitive impairment: cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study. <i>Journal of the Neurological Sciences</i> , 2007 , 252, 106-12	3.2	28
61	Effect of diesel exhaust inhalation on blood markers of inflammation and neurotoxicity: a controlled, blinded crossover study. <i>Inhalation Toxicology</i> , 2016 , 28, 145-53	2.7	27
60	Alzheimer's disease research and development: a call for a new research roadmap. <i>Annals of the New York Academy of Sciences</i> , 2014 , 1313, 1-16	6.5	24
59	An exploration of cognitive subgroups in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2010 , 16, 233-43	3.1	24

58	Fatal familial insomnia: the first account in a family of Chinese descent. <i>Archives of Neurology</i> , 2004 , 61, 122-5		24
57	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. <i>Alzheimer's and Dementia</i> , 2020 , 16, 131-143	1.2	24
56	Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?. <i>Alzheimer's and Dementia</i> , 2006 , 2, 220-33	1.2	22
55	Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. <i>Journal of the Neurological Sciences</i> , 2010 , 288, 142-6	3.2	21
54	Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 483-90	2.6	21
53	What are the treatment options for patients with severe Alzheimer's disease?. <i>CNS Drugs</i> , 2004 , 18, 575-83		20
52	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. <i>Progress in Neurobiology</i> , 2013 , 110, 114-23	10.9	19
51	Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. <i>American Journal of Geriatric Psychiatry</i> , 2008 , 16, 136-44	6.5	19
50	Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004 , 17, 333-6	2.6	19
49	Extrapyramidal features in patients with motor neuron disease and dementia; a clinicopathological correlative study. <i>Acta Neuropathologica</i> , 2004 , 107, 336-40	14.3	19
48	Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. <i>Alzheimer Disease and Associated Disorders</i> , 2009 , 23, 357-64	2.5	18
47	Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , 2008 , 7, 668-70	24.1	18
46	Pharmacological treatment in moderate-to-severe Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2575-82	4	17
45	Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features. <i>Neurology</i> , 2019 , 93, e778-e790	6.5	16
44	Clinical presentation of prodromal frontotemporal dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2007 , 22, 456-67	2.5	16
43	Delayed daily activity and reduced NREM slow-wave power in the APPswe/PS1dE9 mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 78, 74-86	5.6	16
42	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 412-423	5.5	16
41	Gray matter changes in asymptomatic and mutation carriers. <i>NeuroImage: Clinical</i> , 2018 , 18, 591-598	5.3	16

40	Early neuropsychological characteristics of progranulin mutation carriers. <i>Journal of the International Neuropsychological Society</i> , 2014 , 20, 694-703	3.1	15
39	Cognitive impairment no dementia - neuropsychological and neuroimaging characterization of an amnesic subgroup. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 238-47	2.6	15
38	Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. <i>JAMA Neurology</i> , 2019 , 76, 1330-1339	17.2	14
37	Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. <i>Canadian Journal of Neurological Sciences</i> , 2006 , 33, 6-26	1	14
36	The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 449-462	4.3	13
35	Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 102	9	13
34	Global issues in drug development for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 197-207	1.2	12
33	Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. <i>Gender Medicine</i> , 2009 , 6, 345-55		12
32	Primary prevention and delay of onset of AD/dementia. <i>Canadian Journal of Neurological Sciences</i> , 2007 , 34 Suppl 1, S84-9	1	12
31	The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the country. <i>Canadian Journal of Public Health</i> , 2017 , 108, e95-e97	3.2	11
30	Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2021 , 197, 101902	10.9	11
29	Neuropsychological subgroups of cognitively-impaired-not-demented (CIND) individuals: delineation, reliability, and predictive validity. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2005 , 27, 164-88	2.1	10
28	Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. <i>Molecular Neurodegeneration</i> , 2020 , 15, 21	19	8
27	Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication. <i>Journal of Alzheimer's Disease</i> , 2019 , 67, 707-713	4.3	7
26	New lexicon and criteria for the diagnosis of Alzheimer's disease. Authors' reply. <i>Lancet Neurology</i> , 2011 , 10, 300-301	24.1	6
25	Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. <i>BMC Neurology</i> , 2006 , 6, 32	3.1	6
24	Atlas of Alzheimer's Disease 2007 ,		6
23	Neuropsychological characterization of cognitively-impaired-not-demented (CIND) individuals: clinical comparison data. <i>Clinical Neuropsychologist</i> , 2004 , 18, 208-28	4.4	5

22	Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , 2021 , 96, 944-954	6.5	5
21	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1397-1405	1.2	5
20	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. <i>Alzheimer's and Dementia</i> , 2019 , 15, 615-624	1.2	4
19	Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?. <i>Nature Reviews Neurology</i> , 2009 , 5, 128-9	15	4
18	Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2009 , 24, 1174-6	3.9	4
17	Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
16	Neurobehavioral characterization of adult-onset Alexander disease: A family study. <i>Neurology: Clinical Practice</i> , 2017 , 7, 425-429	1.7	3
15	Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12071	6	3
14	Early identification of Alzheimer's disease: what have we learned from mild cognitive impairment?. <i>CNS Spectrums</i> , 2008 , 13, 4-7	1.8	2
13	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , 2021 , 12, 7065	17.4	2
12	16-Year Survival of the Canadian Collaborative Cohort of Related Dementias. <i>Canadian Journal of Neurological Sciences</i> , 2018 , 45, 367-374	1	1
11	Drug Treatment: Cholinesterase Inhibitors 2006 , 131-149		1
10	Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2020 , 34, 357-359	2.5	1
9	Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study.. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 201	9	1
8	Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab.. <i>Canadian Geriatrics Journal</i> , 2021 , 24, 373-378	2.8	0
7	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease.. <i>Nature Communications</i> , 2022 , 13, 1495	17.4	0
6	IC-P-108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION 2014 , 10, P60-P61		
5	P4-038: CREATION OF THE CANADIAN CONSORTIUM FOR NEURODEGENERATION IN AGING 2014 , 10, P796-P796		

- 4 P2-202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION
2014, 10, P546-P547
- 3 F50302: Perspective from the clinical research and manufacturing communities **2013**, 9, P826-P826
- 2 The Dementias: An Overview116-119
- 1 F5-03-02: Biomarkers are Useful in Tertiary Care Clinical Decision-Making **2016**, 12, P370-P370